Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy

James E. Rider; Sean P. Polster; Sangjin Lee; Nathan J. Charles; Neeta Adhikari; Ami Mariash; George Tadros; Jenna Stangland; Ryszard T. Smolenski; Cesare M. Terracciano; Paul J.R. Barton; Emma J. Birks; Magdi H. Yacoub; Leslie W. Miller; Jennifer L Hall

doi:10.1007/s12265-009-9089-6

Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy

James E. Rider, Sean P. Polster, Sangjin Lee, Nathan J. Charles, Neeta Adhikari, Ami Mariash, George Tadros, Jenna Stangland, Ryszard T. Smolenski, Cesare M. Terracciano, Paul J.R. Barton, Emma J. Birks, Magdi H. Yacoub, Leslie W. Miller, Jennifer L Hall

Medicine - Cardiology Division

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The purpose of this study was to determine the effects of chronic treatment with the beta 2 adrenergic receptor agonist clenbuterol on endothelial progenitor cells (EPC) in a well-characterized model of heart failure, the muscle LIM protein knockout (MLP^-/-) mouse. MLP^-/- mice were treated daily with clenbuterol (2 mg/kg) or saline subcutaneously for 6 weeks. Clenbuterol led to a 30% increase in CD31⁺ cells in the bone marrow of MLP^-/- heart failure mice (p∈<∈0.004). Clenbuterol did not improve ejection fraction. Clenbuterol treatment in MLP ^-/- mice was associated with significant changes in the following circulating factors: tissue inhibitor of metalloproteinase-type 1, leukemia inhibitory factor 1, C-reactive protein, apolipoprotein A1, fibroblast growth factor 2, serum glutamic oxaloacetic transaminase, macrophage-derived chemokine, and monocyte chemoattractant protein-3. Clenbuterol treatment in the MLP ^-/- model of heart failure did not rescue heart function, yet did increase CD31⁺ cells in the bone marrow. This is the first evidence that a beta 2 agonist increases EPC proliferation in the bone marrow in a preclinical model of heart failure.

Original language	English (US)
Pages (from-to)	182-190
Number of pages	9
Journal	Journal of cardiovascular translational research
Volume	2
Issue number	2
DOIs	https://doi.org/10.1007/s12265-009-9089-6
State	Published - Jun 2009

Keywords

Beta 2 adrenergic receptor
Clenbuterol
Endothelial progenitor cell
Heart failure
Muscle LIM protein

Access

10.1007/s12265-009-9089-6

Fingerprint Dive into the research topics of 'Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy'. Together they form a unique fingerprint.

Cite this

Rider, J. E., Polster, S. P., Lee, S., Charles, N. J., Adhikari, N., Mariash, A., Tadros, G., Stangland, J., Smolenski, R. T., Terracciano, C. M., Barton, P. J. R., Birks, E. J., Yacoub, M. H., Miller, L. W., & Hall, J. L. (2009). Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy. Journal of cardiovascular translational research, 2(2), 182-190. https://doi.org/10.1007/s12265-009-9089-6

Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy. / Rider, James E.; Polster, Sean P.; Lee, Sangjin; Charles, Nathan J.; Adhikari, Neeta; Mariash, Ami; Tadros, George; Stangland, Jenna; Smolenski, Ryszard T.; Terracciano, Cesare M.; Barton, Paul J.R.; Birks, Emma J.; Yacoub, Magdi H.; Miller, Leslie W.; Hall, Jennifer L.

In: Journal of cardiovascular translational research, Vol. 2, No. 2, 06.2009, p. 182-190.

Research output: Contribution to journal › Article › peer-review

Rider, JE, Polster, SP, Lee, S, Charles, NJ, Adhikari, N, Mariash, A, Tadros, G, Stangland, J, Smolenski, RT, Terracciano, CM, Barton, PJR, Birks, EJ, Yacoub, MH, Miller, LW & Hall, JL 2009, 'Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy', Journal of cardiovascular translational research, vol. 2, no. 2, pp. 182-190. https://doi.org/10.1007/s12265-009-9089-6

Rider, James E. ; Polster, Sean P. ; Lee, Sangjin ; Charles, Nathan J. ; Adhikari, Neeta ; Mariash, Ami ; Tadros, George ; Stangland, Jenna ; Smolenski, Ryszard T. ; Terracciano, Cesare M. ; Barton, Paul J.R. ; Birks, Emma J. ; Yacoub, Magdi H. ; Miller, Leslie W. ; Hall, Jennifer L. / Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy. In: Journal of cardiovascular translational research. 2009 ; Vol. 2, No. 2. pp. 182-190.

@article{fc199d8e22d8411b9cc8aa7d79e98abb,

title = "Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy",

abstract = "The purpose of this study was to determine the effects of chronic treatment with the beta 2 adrenergic receptor agonist clenbuterol on endothelial progenitor cells (EPC) in a well-characterized model of heart failure, the muscle LIM protein knockout (MLP-/-) mouse. MLP-/- mice were treated daily with clenbuterol (2 mg/kg) or saline subcutaneously for 6 weeks. Clenbuterol led to a 30% increase in CD31+ cells in the bone marrow of MLP-/- heart failure mice (p∈<∈0.004). Clenbuterol did not improve ejection fraction. Clenbuterol treatment in MLP -/- mice was associated with significant changes in the following circulating factors: tissue inhibitor of metalloproteinase-type 1, leukemia inhibitory factor 1, C-reactive protein, apolipoprotein A1, fibroblast growth factor 2, serum glutamic oxaloacetic transaminase, macrophage-derived chemokine, and monocyte chemoattractant protein-3. Clenbuterol treatment in the MLP -/- model of heart failure did not rescue heart function, yet did increase CD31+ cells in the bone marrow. This is the first evidence that a beta 2 agonist increases EPC proliferation in the bone marrow in a preclinical model of heart failure.",

keywords = "Beta 2 adrenergic receptor, Clenbuterol, Endothelial progenitor cell, Heart failure, Muscle LIM protein",

author = "Rider, {James E.} and Polster, {Sean P.} and Sangjin Lee and Charles, {Nathan J.} and Neeta Adhikari and Ami Mariash and George Tadros and Jenna Stangland and Smolenski, {Ryszard T.} and Terracciano, {Cesare M.} and Barton, {Paul J.R.} and Birks, {Emma J.} and Yacoub, {Magdi H.} and Miller, {Leslie W.} and Hall, {Jennifer L}",

year = "2009",

month = jun,

doi = "10.1007/s12265-009-9089-6",

language = "English (US)",

volume = "2",

pages = "182--190",

journal = "Journal of Cardiovascular Translational Research",

issn = "1937-5387",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy

AU - Rider, James E.

AU - Polster, Sean P.

AU - Lee, Sangjin

AU - Charles, Nathan J.

AU - Adhikari, Neeta

AU - Mariash, Ami

AU - Tadros, George

AU - Stangland, Jenna

AU - Smolenski, Ryszard T.

AU - Terracciano, Cesare M.

AU - Barton, Paul J.R.

AU - Birks, Emma J.

AU - Yacoub, Magdi H.

AU - Miller, Leslie W.

AU - Hall, Jennifer L

PY - 2009/6

Y1 - 2009/6

N2 - The purpose of this study was to determine the effects of chronic treatment with the beta 2 adrenergic receptor agonist clenbuterol on endothelial progenitor cells (EPC) in a well-characterized model of heart failure, the muscle LIM protein knockout (MLP-/-) mouse. MLP-/- mice were treated daily with clenbuterol (2 mg/kg) or saline subcutaneously for 6 weeks. Clenbuterol led to a 30% increase in CD31+ cells in the bone marrow of MLP-/- heart failure mice (p∈<∈0.004). Clenbuterol did not improve ejection fraction. Clenbuterol treatment in MLP -/- mice was associated with significant changes in the following circulating factors: tissue inhibitor of metalloproteinase-type 1, leukemia inhibitory factor 1, C-reactive protein, apolipoprotein A1, fibroblast growth factor 2, serum glutamic oxaloacetic transaminase, macrophage-derived chemokine, and monocyte chemoattractant protein-3. Clenbuterol treatment in the MLP -/- model of heart failure did not rescue heart function, yet did increase CD31+ cells in the bone marrow. This is the first evidence that a beta 2 agonist increases EPC proliferation in the bone marrow in a preclinical model of heart failure.

AB - The purpose of this study was to determine the effects of chronic treatment with the beta 2 adrenergic receptor agonist clenbuterol on endothelial progenitor cells (EPC) in a well-characterized model of heart failure, the muscle LIM protein knockout (MLP-/-) mouse. MLP-/- mice were treated daily with clenbuterol (2 mg/kg) or saline subcutaneously for 6 weeks. Clenbuterol led to a 30% increase in CD31+ cells in the bone marrow of MLP-/- heart failure mice (p∈<∈0.004). Clenbuterol did not improve ejection fraction. Clenbuterol treatment in MLP -/- mice was associated with significant changes in the following circulating factors: tissue inhibitor of metalloproteinase-type 1, leukemia inhibitory factor 1, C-reactive protein, apolipoprotein A1, fibroblast growth factor 2, serum glutamic oxaloacetic transaminase, macrophage-derived chemokine, and monocyte chemoattractant protein-3. Clenbuterol treatment in the MLP -/- model of heart failure did not rescue heart function, yet did increase CD31+ cells in the bone marrow. This is the first evidence that a beta 2 agonist increases EPC proliferation in the bone marrow in a preclinical model of heart failure.

KW - Beta 2 adrenergic receptor

KW - Clenbuterol

KW - Endothelial progenitor cell

KW - Heart failure

KW - Muscle LIM protein

UR - http://www.scopus.com/inward/record.url?scp=67349140886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349140886&partnerID=8YFLogxK

U2 - 10.1007/s12265-009-9089-6

DO - 10.1007/s12265-009-9089-6

M3 - Article

C2 - 20559986

AN - SCOPUS:67349140886

VL - 2

SP - 182

EP - 190

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 2

ER -